Ramelteon - Takeda
Alternative Names: Ramelteon SL; Ramelteon sublingual; Rozerem; TAK-375; TAK-375SLLatest Information Update: 25 Jul 2024
At a glance
- Originator Takeda
- Developer Sun Pharmaceutical Industries; Takeda
- Class Antidementias; Antidepressants; Anxiolytics; Indenes; Mood stabilisers; Sleep disorder therapies; Small molecules
- Mechanism of Action Melatonin MT1 receptor agonists; Melatonin MT2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Insomnia
- Discontinued Alzheimer's disease; Bipolar depression; Bipolar disorders; Circadian rhythm sleep disorders
Most Recent Events
- 22 Jul 2024 Nanjing Chia-tai Tianqing Pharmaceutical plans a phase III trial for Insomnia in China (PO, tablet) (NCT06512363)
- 14 Apr 2021 Discontinued - Phase-I for Insomnia (In adolescents, In children) in USA (PO) (Takeda pipeline, April 2021)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Insomnia(In adolescents, In children) in USA (PO, Tablet)